Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

ZAP70 Methylation Is An Independent Prognostic Biomarker For Front Line Therapy Of Chronic Lymphocytic Leukemia : Results From The UK LRF CLL4 Trial

Anton Parker, Ben Gregory, Zadie Davis, Monica Else, MA, MSc, Matthew JJ Rose-Zerilli, PhD, Jonathan C Strefford, Daniel Catovsky, MD, DSc(Med), David Oscier

Blood (2013) 122 (21): 4137.

https://doi.org/10.1182/blood.V122.21.4137.4137

Published: 2013

Journal Articles

Gene Expression Profiling Classifies Splenic Marginal Zone Lymphoma and Hairy Cell Leukemia-Variant as Related Diseases That Are Distinct From Typical Hairy Cell Leukemia.

Sarah L Hockley, PhD, Alison Morilla, Andrew Wotherspoon, MD, PhD, Brian A Walker, PhD, Nicholas J Dickens, PhD, Daniel Catovsky, MD, DSc(Med), Gareth J Morgan, MD, PhD, Estella Matutes, MD, PhD, David Gonzalez, PhD

Blood (2009) 114 (22): 3467.

https://doi.org/10.1182/blood.V114.22.3467.3467

Published: 2009

Journal Articles

High Resolution Genomic Profiling Using Single Nucleotide Polymorphism Microarrays Reveals Novel Genomic Lesions in Hairy Cell Leukaemia and Hairy-Cell Leukaemia Variant

Sarah L Hockley, PhD, Monica Else, MA, MSc, Paola E Leone, PhD, Brian A Walker, Alison Morilla, Daniel Catovsky, MD, DSc(Med), Gareth J Morgan, MD, PhD, Estella Matutes, MD, PhD, David Gonzalez, PhD

Blood (2008) 112 (11): 3136.

https://doi.org/10.1182/blood.V112.11.3136.3136

Published: 2008

Journal Articles

Genome-Wide Profiling of DNA Copy Number Variation in CLL Cases Lacking 17p- (TP53) or 11q- (ATM) Abnormalities Selected from the CLL4 Study

Sarah L Hockley, PhD, David Gonzalez, PhD, Vasantha Brito-Babapulle, PhD, Monica Else, MA, MSc, Paola E Leone, Brian A Walker, Estella Matutes, MD, PhD, Claire E Dearden, MD, Daniel Catovsky, MD, DSc(Med), Gareth J Morgan, MD, PhD

Blood (2008) 112 (11): 3140.

https://doi.org/10.1182/blood.V112.11.3140.3140

Published: 2008

Journal Articles

Long-Term Follow-up of 228 Hairy Cell Leukemia Patients Treated with Pentostatin or Cladribine with 15.4 Years Median Time from Diagnosis.

Monica Else, MA, MSc, Claire E. Dearden, MD, Estella Matutes, MD, Ama Z S Rohatiner, MD, Steve A N Johnson, MD, Nigel T J O’Connor, MD, Andy Haynes, MD, Nnenna Osuji, MD, Daniel Catovsky, MD, DSc(Med)

Blood (2008) 112 (11): 2101.

https://doi.org/10.1182/blood.V112.11.2101.2101

Published: 2008

Journal Articles

The Lack of Survival Differences in Randomised Trials in CLL May Be Related to the Effect of Second Line Therapies. A Report from the LRF CLL4 Trial.

Daniel Catovsky, MD, DSc, Monica Else, MA MSc, Sue Richards, D Phil, Peter Hillmen, MD PhD

Blood (2006) 108 (11): 304.

https://doi.org/10.1182/blood.V108.11.304.304

Published: 2006

Journal Articles

Early Results from LRF CLL4: A UK Multicenter Randomized Trial.

Daniel Catovsky, MD, DSc (Med), Susan Richards, D Phil, Peter Hillmen, MD, PhD

Blood (2005) 106 (11): 716.

https://doi.org/10.1182/blood.V106.11.716.716

Published: 2005

Journal Articles

Quality of Life in the LRF CLL4 Trial.

Monica Else, MSc, Alastair G. Smith, MD, Kim Hawkins, MSc, Shirley Crofts, MSc, Margaret Course, BA, Susan Richards, D.Phil, Daniel Catovsky, MD DSc(Med)

Blood (2005) 106 (11): 2111.

https://doi.org/10.1182/blood.V106.11.2111.2111

Published: 2005

Journal Articles

Incidence of Hemolytic Anemia after Chemotherapy in the CLL4 Trial. A Possible Protective Role for Fludarabine Plus Cyclophosphamide.

Daniel Catovsky, MD, DSC, Sue Richards, MD

Blood (2004) 104 (11): 480.

https://doi.org/10.1182/blood.V104.11.480.480

Published: 2004

Journal Articles

Response to Therapy and Survival in CLL Is Influenced by Genetic Markers. Preliminary Analysis from the LRF CLL4 Trial.

Daniel Catovsky, MD, DSc, Sue Richards, PhD, Estella Matutes, Anna Burford, BSc, Vasantha Brito-Babapulle, PhD, Claire Dearden, MD, Philip Morris, PhD, Andrew Pettitt, PhD, MRCPath

Blood (2004) 104 (11): 13.

https://doi.org/10.1182/blood.V104.11.13.13

Published: 2004

Journal Articles

Gender as a Prognostic Factor in CLL. Biological Pointers to the Improved Outcome of Women.

Daniel Catovsky, MD, DSC, Estella Matutes, MD, PhD, Alison Morilla, BSc, Anna Burford, BSc, Vasantha Brito-Babapulle, PhD, Ilaria Del-Giudice, MD, Jennifer Orchard, MD, David G. Oscier, MD, Jim Halsey, PhD, Sue Richards, PhD

Blood (2004) 104 (11): 957.

https://doi.org/10.1182/blood.V104.11.957.957

Published: 2004

NARROW

ZAP70 Methylation Is An Independent Prognostic Biomarker For Front Line Therapy Of Chronic Lymphocytic Leukemia : Results From The UK LRF CLL4 Trial

Gene Expression Profiling Classifies Splenic Marginal Zone Lymphoma and Hairy Cell Leukemia-Variant as Related Diseases That Are Distinct From Typical Hairy Cell Leukemia.

High Resolution Genomic Profiling Using Single Nucleotide Polymorphism Microarrays Reveals Novel Genomic Lesions in Hairy Cell Leukaemia and Hairy-Cell Leukaemia Variant

Genome-Wide Profiling of DNA Copy Number Variation in CLL Cases Lacking 17p- (TP53) or 11q- (ATM) Abnormalities Selected from the CLL4 Study

Long-Term Follow-up of 228 Hairy Cell Leukemia Patients Treated with Pentostatin or Cladribine with 15.4 Years Median Time from Diagnosis.

The Lack of Survival Differences in Randomised Trials in CLL May Be Related to the Effect of Second Line Therapies. A Report from the LRF CLL4 Trial.

Early Results from LRF CLL4: A UK Multicenter Randomized Trial.

Quality of Life in the LRF CLL4 Trial.

Incidence of Hemolytic Anemia after Chemotherapy in the CLL4 Trial. A Possible Protective Role for Fludarabine Plus Cyclophosphamide.

Response to Therapy and Survival in CLL Is Influenced by Genetic Markers. Preliminary Analysis from the LRF CLL4 Trial.

Gender as a Prognostic Factor in CLL. Biological Pointers to the Improved Outcome of Women.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only